Literature DB >> 16685464

Age at diagnosis and loss of heterozygosity on chromosome 1p and 19q in oligodendroglial tumors.

M Hergersberg, L Mariani, E Vassella, C Murtin, J Weis, M Moschopulos, H Laeng, H Landolt, A Huber, U Roelcke.   

Abstract

The age distribution and incidence of loss of heterozygosity (LOH) of 1p and 19q was analyzed in 85 oligodendroglial tumors WHO II and III. The peak of tumor manifestation was in the age group of 35 to 55 years. There was no association between age at diagnosis and LOH incidence. We conclude that the prognostic effect of age on survival is not mediated by LOH 1p/19q.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16685464     DOI： 10.1007/s11060-006-9177-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  14 in total

1.  Molecular genetic evidence for subtypes of oligoastrocytomas.

Authors:  D Maintz; K Fiedler; J Koopmann; B Rollbrocker; S Nechev; D Lenartz; A P Stangl; D N Louis; J Schramm; O D Wiestler; A von Deimling
Journal:  J Neuropathol Exp Neurol       Date:  1997-10       Impact factor: 3.685

2.  Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma.

Authors:  F M Ross; A H Ibrahim; A Vilain-Holmes; M O Winfield; L Chiecchio; R K M Protheroe; P Strike; J L Gunasekera; A Jones; C J Harrison; G J Morgan; N C P Cross
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

3.  Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis.

Authors:  G Bauman; K Lote; D Larson; L Stalpers; C Leighton; B Fisher; W Wara; D MacDonald; L Stitt; J G Cairncross
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-11-01       Impact factor: 7.038

Review 4.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  J Neuropathol Exp Neurol       Date:  2005-06       Impact factor: 3.685

5.  Prognostic factors for survival in adult patients with cerebral low-grade glioma.

Authors:  Francesco Pignatti; Martin van den Bent; Desmond Curran; Channa Debruyne; Richard Sylvester; Patrick Therasse; Denes Afra; Philippe Cornu; Michel Bolla; Charles Vecht; Abul B M F Karim
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

6.  Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival.

Authors:  S Kunwar; G Mohapatra; A Bollen; K R Lamborn; M Prados; B G Feuerstein
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

Review 7.  Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.

Authors:  Guido Reifenberger; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2003-02       Impact factor: 3.685

8.  Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.

Authors:  Yoshikazu Okamoto; Pier-Luigi Di Patre; Christoph Burkhard; Sonja Horstmann; Benjamin Jourde; Michael Fahey; Danielle Schüler; Nicole M Probst-Hensch; M Gazi Yasargil; Yasuhiro Yonekawa; Urs M Lütolf; Paul Kleihues; Hiroko Ohgaki
Journal:  Acta Neuropathol       Date:  2004-04-28       Impact factor: 17.088

9.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

Authors:  Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

10.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors:  J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal:  J Natl Cancer Inst       Date:  1998-10-07       Impact factor: 13.506
View more
  1 in total

1.  Molecular profile of oligodendrogliomas in young patients.

Authors:  Vaishali Suri; Prerana Jha; Shipra Agarwal; Pankaj Pathak; Mehar Chand Sharma; Vikas Sharma; Sudhanshu Shukla; Kumaravel Somasundaram; Ashok Kumar Mahapatra; Shashank Sharad Kale; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2011-10       Impact factor: 12.300
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.